



## A Novel Phosphatidylserine-Binding Molecule Enhances Anti-Tumor T Cell Responses by Targeting Immune Suppressive Exosomes in Human Tumor Microenvironments

### Untreated Tumor



### Tumor + ExoBlock



### Authors

Maulasri Bhatta, Gautam N. Shenoy, Jenni L. Loyall, Brian D. Gray, Meghana Bapardekar, Alexis Conway, Hans Minderman, Raymond J. Kelleher Jr, Beatriz M. Carreno, Gerald P. Linette, Leonard D. Shultz, Kunle Odunsi, Sathy V. Balu-Iyer, Koon Yan Pak and Richard B. Bankert

Correspondence: [rbankert@buffalo.edu](mailto:rbankert@buffalo.edu)

### In Brief

- ExoBlock binds phosphatidylserine, a lipid associated with exosome-mediated immune suppression, with high avidity.
- ExoBlock reverses exosome-mediated suppression of T cell function *in vitro*.
- Treatment with ExoBlock enhances anti-tumor T cell responses in the tumor microenvironment *in vivo*, and is associated with an increase in T cell numbers and function, which in turn result in a decrease in the tumor burden as well as in the numbers of circulating immunosuppressive exosomes.